Targanta Files Oritavancin NDA For cSSSI, Aiming To Tackle Vancomycin Market
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.
Third owner of Lilly-developed compound touts antibiotic’s shorter course of treatment and dosing advantages over competing therapies.